News | October 13, 2025
Cadila launches allergy relief tablet Dlorfast-M
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
Subscribe To Our Newsletter & Stay Updated
